Form D · Biotechnology
PolyCore Therapeutics, Inc.
Philadelphia, PA · CIK 0001914733
Offering snapshot reported Mar 17, 2022 · SEC filing
- Reported sold
- $4.71M Offering amount: $4.71M
- Investors reported
- 5 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 11, 2022 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Mar 17, 2022 | Initial | $4,713,623 | No comparison | 5 | SEC filing |
Offering details
- Securities
- Equity, Other
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-437808
Common Stock
Source: Form D, filed Mar 17, 2022. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Kelly Beck | Director, Executive, Promoter |
| Frederick Callori | Director |
| Christopher Cashman | Director |
| Chris Garabedian | Director |
| James B. Harris | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
3180 Chestnut Street, Suite 104
Philadelphia, PA, 19104
Philadelphia, PA, 19104